HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (7) Citing Articles via Google Scholar Google Scholar Articles by Wansa, K D S. A. Articles by Muscat, G. E O Search for Related Content PubMed PubMed Citation Articles by Wansa, K D S. A. Articles by Muscat, G. E O

Institute for Molecular Bioscience, University of Queensland St Lucia, 4072 Queensland, Australia

(Requests for offprints should be addressed to G.Muscat{at}imb.uq.edu.au)

The NR4A1–3 (Nur77, NURR1 and NOR-1) subfamily of nuclear hormone receptors (NRs) has been implicated in Parkinson’s disease, schizophrenia, manic depression, atherogenesis, Alzheimer’s disease, rheumatoid arthritis, cancer and apoptosis. This has driven investigations into the mechanism of action, and the identification of small molecule regulators, that may provide the platform for pharmaceutical and therapeutic exploitation. Recently, we found that the purine antimetabolite 6-Mercaptopurine (6-MP), which is widely used as an anti-neoplastic and anti-inflammatory drug, modulated the NR4A1–3 subfamily. Interestingly, the agonist-mediated activation did not involve modulation of primary coactivators’ (e.g. p300 and SRC-2/GRIP-1) activity and/or recruitment. However, the role of the subsequently recruited coactivators, for example CARM-1 and TRAP220, in 6-MP-mediated activation of the NR4A1–3 subfamily remains obscure. In this study we demonstrate that 6-MP modulates the activity of the coactivator TRAP220 in a dose-dependent manner. Moreover, we demonstrate that TRAP220 potentiates NOR-1-mediated transactivation, and interacts with the NR4A1–3 subgroup in an AF-1-dependent manner in a cellular context. The region of TRAP220 that mediated 6-MP activation and NR4A interaction was delimited to amino acids 1–800, and operates independently of the critical PKC and PKA phosphorylation sites. Interestingly, TRAP220 expression does not increase the relative induction by 6-MP, however the absolute level of NOR-1-mediated trans-activation is increased. This study demonstrates that 6-MP modulates the activity of the NR4A subgroup, and the coactivator TRAP220.

This article has been cited by other articles:

				M. A. Pearen, S. A. Myers, S. Raichur, J. G. Ryall, G. S. Lynch, and G. E. O. Muscat The Orphan Nuclear Receptor, NOR-1, a Target of {beta}-Adrenergic Signaling, Regulates Gene Expression that Controls Oxidative Metabolism in Skeletal Muscle Endocrinology, June 1, 2008; 149(6): 2853 - 2865. [Abstract] [Full Text] [PDF]

				A. G. Smith, N. Luk, R. A. Newton, D. W. Roberts, R. A. Sturm, and G. E. O. Muscat Melanocortin-1 Receptor Signaling Markedly Induces the Expression of the NR4A Nuclear Receptor Subgroup in Melanocytic Cells J. Biol. Chem., May 2, 2008; 283(18): 12564 - 12570. [Abstract] [Full Text] [PDF]

				N. M.M. Pires, T. W.H. Pols, M. R. de Vries, C. M. van Tiel, P. I. Bonta, M. Vos, E. K. Arkenbout, H. Pannekoek, J. W. Jukema, P. H.A. Quax, et al. Activation of Nuclear Receptor Nur77 by 6-Mercaptopurine Protects Against Neointima Formation Circulation, January 30, 2007; 115(4): 493 - 500. [Abstract] [Full Text] [PDF]